




**ΚΥΠΡΙΑΚΟ ΓΡΑΦΕΙΟ ΔΙΠΛΩΜΑΤΩΝ
ΕΥΡΕΣΙΤΕΧΝΙΑΣ
THE PATENT OFFICE OF CYPRUS**

**ΑΡΙΘΜΟΣ ΔΗΜΟΣΙΕΥΣΗΣ CY1600
PUBLICATION NUMBER**

ΑΡΙΘΜΟΣ ΔΗΜΟΣΙΕΥΣΗΣ
ΓΡΑΦΕΙΟΥ ΔΙΠΛΩΜΑΤΩΝ ΕΥΡΕΣΙΤΕΧΝΙΑΣ
ΗΝΩΜΕΝΟΥ ΒΑΣΙΛΕΙΟΥ
UK PATENT OFFICE
PUBLICATION NUMBER GB2204792

Το έγγραφο που παρουσιάζεται πιο κάτω καταχωρήθηκε στο «Γραφείο Διπλωμάτων Ευρεσιτεχνίας» στην Αγγλία σύμφωνα με το Νόμο Κεφ. 266 πριν την 1^η Απριλίου 1998. Δημοσίευση έγινε μετέπειτα από το Γραφείο Διπλωμάτων Ευρεσιτεχνίας του Ηνωμένου Βασιλείου μόνο στην Αγγλική γλώσσα.

**The document provided hereafter was filed at "The Patent Office"
in England under the law CAP.266 before the 1st of April 1998.
It was published afterwards by the UK patent office only in English.**

(12) **UK Patent Application** (19) **GB** (11) **2 204 792** (13) **A**
(43) Application published 23 Nov 1988

(21) Application No 8811378

(22) Date of filing 13 May 1988

(30) Priority data

(31) 8711432
8802926

(32) 14 May 1987
9 Feb 1988

(33) GB

(71) Applicant

Glaxo Group Limited

(Incorporated in United Kingdom)

Clarges House, 6-12 Clarges Street,
London, W1Y 8DH

(72) Inventors

Michael Bernard James
Leonard Godfrey Elliott

(74) Agent and/or Address for Service

Frank B Dehn & Co
Imperial House, 15-19 Kingsway, London, WC2B 6UZ

(51) INT CL⁴

A61K 9/30 31/545

(52) Domestic classification (Edition J):

A5B 180 216 21Y 802 822 833 840 841 KB

(56) Documents cited

GB A 2181052 GB A 2081092 GB 1323161

(58) Field of search

A5B

Selected US specifications from IPC sub-class
A61K

(54) **Cefuroxime axetil compositions**

(57) Cefuroxime axetil in particulate form is coated with an integral coating of a lipid or mixture of lipids which serves to mask the bitter taste of cefuroxime axetil but disperses or dissolves on contact with gastro-intestinal fluid.

The resulting particles may be incorporated into pharmaceutical compositions for oral administration, for instance aqueous suspensions.

Pharmaceutical Composition

This invention is concerned with pharmaceutical compositions containing the 1-acetoxyethyl ester of cefuroxime, which has the approved name 'cefuroxime axetil'.

5 Cefuroxime, as disclosed in British Patent Specification No. 1453049, is a valuable broad spectrum antibiotic characterised by high activity against a wide range of gram-positive and gram-negative micro-organisms, this property being enhanced by the very
10 high stability of the compound to β -lactamases produced by a range of gram negative microorganisms. Cefuroxime and its salts are principally of value as injectable antibiotics since they are poorly absorbed from the gastro-intestinal tract.

15 We have found that esterification of the carboxyl group of cefuroxime as a 1-acetoxyethyl ester to give cefuroxime axetil improves the effectiveness on oral administration as disclosed in British Patent Specification No. 1571683. The presence of the 1-
20 acetoxyethyl esterifying group results in significant absorption of the compound from the gastro-intestinal tract, whereupon the esterifying group is hydrolysed by enzymes present in, for example, serum and body tissues to yield the antibiotically active acid.
25 It is particularly advantageous to employ cefuroxime axetil in an amorphous form as disclosed in British Patent Specification No. 2127401.

Cefuroxime axetil has therefore extended the valuable therapeutic potential of cefuroxime by making
30 available a form of the antibiotic which may be administered orally rather than by injection only.

A convenient means of presenting antibiotics for oral administration is in the form of granules

which may be administered as a solution or suspension or taken with a draught of water. Solutions or suspensions of granules as, for example, a syrup are particularly convenient for oral administration of antibiotics

- 5 to children. However, cefuroxime axetil has an extremely bitter taste which is long lasting and which cannot be adequately masked by the addition of sweeteners and flavours to conventional granule presentations.

- Another problem arises from the tendency of
- 10 cefuroxime axetil, both in crystalline form and the amorphous form mentioned above, to form a gelatinous mass when contacted with aqueous media. This gelling effect is temperature dependent but does occur at temperatures of about 37°C, i.e. at the physiological
- 15 temperatures at which the disintegration of an orally administered granule would take place. Where there is a relatively slow dispersion of cefuroxime axetil into the surrounding aqueous medium following ingestion, there is the risk that cefuroxime axetil
- 20 present in the composition may gel. Such gel formation would lead to poor dissolution of the cefuroxime axetil and hence poor absorption from the gastrointestinal tract, i.e. low bioavailability. In the case of granule formulations the use of particles
- 25 of small diameter and high surface area is desirable to avoid such gelling.

- In the formulation of cefuroxime axetil into granules it is important to avoid release of the drug into any liquid suspension which is used or,
- 30 indeed, into the mouth. Such problems may be minimised by formulating the cefuroxime axetil as lipid coated particles the coat of which has limited permeability to water. Any holes in the coating would mean that the bitter taste was not effectively
- 35 masked and it is important therefore that the coating is integral.

We have thus found that the extremely bitter taste of cefuroxime axetil may be overcome by the application to cefuroxime axetil particles of integral lipid coatings which are substantially insoluble in water but which are readily dispersed or dissolved in gastro-intestinal fluid. The formulated coated particles, while not releasing the bitter cefuroxime axetil in the wet environment of the mouth, break down upon contact with gastro-intestinal fluid, thus allowing rapid dispersion and dissolution in the gastro-intestinal tract.

British Patent Specification No. 2081092 discusses the use of wax (i.e. lipid) coatings for the purpose of masking the bitterness of medicinal substances. It is however explained at page 1, line 4, to page 2, line 5, that the use of wax coatings results in poor dissolution of the medicinal substances in the alimentary canal as exemplified by compositions described in British Patent Specification No. 1323161 which contain penamecillin coated with lipids containing hydrogenated castor oil; it is proposed in British Patent Specification No. 2081092 to overcome this problem by mixing the waxes used with water-swellaable materials. This would clearly not be appropriate for cefuroxime axetil granules which when made up into aqueous suspensions must retain their taste masking properties on storage for up to 14 days. If a coating containing water-swellaable materials were to be used, then inevitably the taste masking effect of the coating would be lost on storage in aqueous media for this period of time.

Lipid coatings have hitherto also been used to give free flowing powders (see for instance US Patent No. 3247065) and in the preparation of sustained release medicaments which may be formulated as tablets or capsules (see for instance US Patent No. 3146167). These products have however in general been of much

larger particle size than would be acceptable for incorporation into an aqueous suspension for oral administration. Moreover in view of: (i) the past use of lipid coatings to provide sustained release medicaments, (ii) the problem of low bioavailability of the medicinal substance where wax coatings are used as described in British Patent Specification No. 2081092 and (iii) the known tendency for cefuroxime axetil to gel with consequent poor absorption from the gastro-intestinal tract, it is particularly surprising that cefuroxime axetil particles provided with integral lipid coatings do allow rapid dispersion and dissolution in the gastro-intestinal tract and thus do enable acceptable levels of bioavailability to be achieved.

According to one aspect of the invention therefore we provide a composition comprising cefuroxime axetil in particulate form, the particles being provided with integral coatings of a lipid or a mixture of lipids which are insoluble in water and which serve to mask the bitter taste of cefuroxime axetil upon oral administration but which disperse or dissolve on contact with gastro-intestinal fluid.

In order to provide taste-masked particles of cefuroxime axetil suitable for oral administration the melting point of the lipid used should be sufficiently high to prevent melting of the coated particles in the mouth, thereby leading to release of the bitter tasting active ingredient, but not so high that the cefuroxime axetil active ingredient itself melts and/or becomes chemically degraded during the coating process. Thus the lipid or mixture of lipids for use in the present invention will conveniently have a melting point of from 30 to 80°C and preferably from 40 to 70°C. Where the composition according to the invention contains amorphous cefuroxime axetil, the melting point of the lipid or mixture of lipids is still more preferably from 45 to 60°C.

Suitable lipids include fatty acids or monohydric alcohols thereof, fixed oils, fats, waxes, sterols, phospholipids and glycolipids. The lipid may, for example, be a high molecular weight (C_{10-30}) straight chain saturated or unsaturated aliphatic acid, such as stearic acid or palmitic acid; a triglyceride for example a glyceryl ester of a high molecular weight (C_{10-30}) aliphatic acid, such as glyceryl trilaurate or glyceryl trimyristate; a partially hydrogenated vegetable oil such as cottonseed oil or soyabean oil; a wax for example beeswax or carnauba wax; a high molecular weight (C_{10-30}) straight chain aliphatic alcohol such as stearyl alcohol or cetyl alcohol; or a mixture thereof. Mixtures of high molecular weight fatty acids such as mixtures of stearic and palmitic acids, mixtures of high molecular weight straight chain aliphatic alcohols, such as cetostearyl alcohol, mixtures of partially hydrogenated cottonseed and soyabean oils and mixtures of high molecular weight aliphatic acids and glyceryl esters such as a mixture of stearic acid and glyceryl trilaurate may, for example, be used. A particularly preferred lipid providing good bioavailability and having physical properties particularly compatible with cefuroxime axetil is stearic acid in admixture with palmitic acid in a ratio in the range 3:7 to 7:3 by weight, more preferably about 1:1 by weight.

The composition of the invention may contain cefuroxime axetil in crystalline form or more preferably in amorphous form, for example as described in British Patent Specification No. 2127401.

If desired, the cefuroxime axetil may be first undercoated with a substance with coating properties. This undercoating may serve to protect the cefuroxime axetil where it may be chemically sensitive to the lipid with which it is coated.

The substance with coating properties used for the undercoating is preferably water-soluble and is preferably a film-forming agent. Film-forming agents which are useful include polysaccharides such as maltodextrin, alkylcelluloses such as methyl or ethyl cellulose, hydroxyalkylcelluloses (e.g. hydroxypropyl-cellulose or hydroxypropylmethylcelluloses), polyvinyl-pyrrolidone and polymers based on methacrylic acid. These may be applied from aqueous or non-aqueous systems as appropriate. Maltodextrin is particularly preferred. Undercoated particles in which the cefuroxime axetil is present at a concentration of 10 to 30% by weight, for example about 20% by weight may conveniently be used for coating by the lipid.

The lipid coated particles according to the invention will preferably contain from 5 to 90%, more preferably from 5 to 50% and still more preferably from 5 or 10 to 30% by weight of cefuroxime axetil. Where the cefuroxime axetil is first undercoated the lipid coated particles most preferably contain from 5 to 15% by weight of cefuroxime axetil; where no undercoating is employed the lipid coated particles most preferably contain from 10 to 30% by weight of cefuroxime axetil.

In general, particles provided with an integral lipid coating to mask the bitter taste of the cefuroxime axetil can have a diameter of less than 250 microns. Coated particles with diameters in the range of from 1 to 250 microns are thus preferred. The size of the coated particles is an important factor with respect to the bioavailability of the cefuroxime axetil and the acceptability of such products for oral administration, average particle sizes in excess of about 250 microns mean diameter by volume giving an undesirable gritty taste. Pharmaceutical products according to the invention will thus generally take the form of coated particles having a mean diameter

by volume of less than 100 microns, e.g. in the range of 20 to 100 microns or more especially 30 to 60 microns. It is convenient to apply the integral lipid coatings to particles which prior to coating have a mean diameter by volume of less than 80 microns, e.g. in the range of 5 to 50 microns. For example, amorphous cefuroxime axetil can be prepared in the form of hollow microspheres having a mean diameter by volume in the range of 5 to 50 microns by a spray-drying method as described in British Patent Specification No. 2127401.

The coated particles of the invention may conveniently be prepared by atomising a dispersion of particulate cefuroxime axetil in a molten lipid and cooling the coated particles thereby obtained and such a process constitutes a further feature of the invention. The dispersion may be prepared by adding particulate cefuroxime axetil to the molten lipid or mixture of lipids or alternatively mixing the ingredients of the dispersion together in the solid state and then melting the lipid or mixture of lipids.

The particulate cefuroxime axetil can be dispersed in the molten lipid using conventional techniques, for example, using a high shear mixer. Generally, the temperature of the molten lipid will be 10 to 20°C above its melting point.

A particularly preferred dispersion for preparing lipid coated particles of cefuroxime axetil is a dispersion of cefuroxime axetil in a mixture of stearic acid and palmitic acid in a ratio in the range 3:7 to 7:3 by weight, preferably in the ratio of about 1:1 by weight. The amount of cefuroxime axetil in the dispersions for preparing lipid-coated particles according to the invention is calculated to provide the desired amount of cefuroxime axetil in the coated particle as discussed above. The molten dispersion is atomised to give particles of lipid-coated cefuroxime

axetil on cooling. Techniques which may be used include the use of conventional atomisers such as rotary atomisers, pressure nozzles, pneumatic nozzles and sonic nozzles.

5 The use of a pneumatic nozzle and in particular a two-fluid internal or external mixing pneumatic nozzle atomiser fitted in a standard spray drying/chilling apparatus is particularly convenient. A suitable internal mixing two fluid nozzle is as for example
10 described in British Patent Specification No. 1412133.

 In the atomisation process using an internal mixing two-fluid nozzle atomiser, which atomisation process constitutes a preferred feature of the invention, the molten lipid dispersion of cefuroxime axetil
15 will generally be supplied to the atomiser head at a temperature in the range of 60 to 80°C, preferably 65 to 75°C, the precise temperature depending on the particular lipid material to be used. The atomising gas supplied to the nozzle may be air or an inert
20 gas such as dry nitrogen. The temperature of the gas will generally be within the range 60 to 90°C, preferably 70 to 85°C with the precise temperature dependant upon the particular lipid material being used. We have found that in the coating process,
25 the temperature at which the molten dispersion is maintained is preferably in the range of 10 to 20°C above the melting point of the lipid or mixture of lipids used in order to provide a dispersion having the desired viscosity for atomisation. The atomising
30 pressure is desirably controlled in order to produce coated particles of preferred size as referred to above.

 The coated particles may be solidified and collected by conventional techniques. The coated
35 particles may conveniently be solidified by applying a stream of cool air or preferably dry nitrogen to the spray chamber at a temperature of for example

0 to 30°C, preferably 5-20°C such that cooling and solidification of the particles is complete. The product may for example be collected using a cyclone separator, a dust filter, or under gravity.

5 Where cefuroxime axetil for dispersion in the lipid material is undercoated, the undercoating substance may be applied to the cefuroxime axetil using conventional coating techniques, for example, spray coating using a fluidised bed granulator, a
10 centrifugal fluidised bed coater or a spray drier or coating with a rotary granulator. In the preparation of lipid coated particles by the process described above, the concentration of undercoated cefuroxime axetil in the molten dispersion is conveniently in
15 the range of 20 to 80% by weight, more conveniently 35 to 65% by weight. The lipid coating thus preferably provides 20 to 80%, most preferably 35 to 65%, by weight of coated particles according to the invention which are prepared from undercoated cefuroxime axetil.

20 The particulate products according to the invention may be used in pharmaceutical compositions for oral administration and may be presented as a suspension for administration, as a dry product for constitution with water or other suitable vehicle before use for
25 administration as a suspension, or for direct administration and then washed down with water or other suitable liquid. Such preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending and/or binding agents e.g. alkylcellu-
30 loses such as methyl cellulose, hydroxyalkylcelluloses such as hydroxypropylcellulose and hydroxypropyl-methylcellulose, sodium carboxymethylcellulose or mixtures thereof, pregelatinised maize starch or polyvinylpyrrolidone; fillers, e.g. sucrose, starch,
35 lactose and micro-crystalline cellulose; adsorbents and flow aids such as talc, aluminium oxide and silicon dioxide; emulsifying or thickening agents e.g. lecithin

or aluminium stearates; surface active agents, e.g. sodium lauryl sulphate or non-ionic polyoxyethylene-polyoxypropylene copolymers; preservatives e.g. methyl or propyl hydroxybenzoates or sorbic acid; colouring agents, e.g. titanium dioxide pigments, lake colours and iron oxide pigments; flavouring agents e.g. 'mint' flavours such as peppermint flavouring agents; and bulk sweeteners e.g. sorbitol and sucrose or artificial sweeteners e.g. saccharin sodium and sodium cyclamate.

10 Where the additives are in solid form, the particles of the invention may be blended with the additives in the form of a dry mix or the additives may themselves be formulated into an excipient granule for blending with the active particles of the invention, or more
15 preferably the particles of the invention may be granulated together with the additives using conventional techniques.

Such granulation techniques include the use of conventional granulators e.g. spray granulators,
20 rotary granulators, centrifugal fluidised bed granulators, high speed mixer granulators and extrusion and comminution techniques. Drying may be carried out by conventional techniques, for example in the granulator or in a drying oven or hot air drier. It is, of course,
25 desirable that the granules should be prepared by a method which is convenient to provide granules of the desired size; this may generally be achieved by conventional adjustment of the conditions of granulation and, if necessary, by screening of the granules thus
30 produced.

Where the pharmaceutical composition for oral administration is presented as a suspension, this may be in an aqueous or non-aqueous vehicle provided this is compatible with the lipid coating material.
35 Suitable non-aqueous vehicles for suspension include, for example, almond oil, fractionated coconut oil or oily esters.

In a further aspect, therefore, the invention provides a pharmaceutical composition for oral administration comprising a composition according to the invention together with one or more pharmaceutical carriers or
5 excipients.

In particular there is provided a granule for oral administration comprising the coated particles of cefuroxime axetil of the invention together with one or more pharmaceutically acceptable excipients. The excipient material
10 preferably comprises a sweetener, for example sucrose. Other pharmaceutically acceptable excipients which may be present include those described above. The granules may be prepared using conventional methods as described above. Granulation may be achieved, for example, by blending of
15 the ingredients, and granulation with water. The resulting granules may be passed through a screen to remove particles of too large a size. Granules of a diameter below 1000 microns, and particularly below 800 microns are preferred.

Where the particles of the invention are formulated
20 in an aqueous medium, this advantageously contains an orally acceptable solute at relatively high concentration since this assists in maintaining the taste-masking properties of the lipid coating. Thus, for example, the aqueous medium may contain a sugar, e.g. sucrose,
25 advantageously in the concentration range 50 to 85 weight percent, preferably 60 to 80 weight percent. Such a solute can conveniently be incorporated into the granules containing the particulate product according to the invention. In the case of sucrose this also serves
30 as a sweetener and preservative.

The pharmaceutical products of the invention, formulated for oral administration as a suspension, may be constituted with a suitable quantity of water, for use in oral administration of cefuroxime axetil. The
35 particles will typically be presented so as to give a multidose suspension containing the equivalent of 500 mg to 10 g cefuroxime or a single dose suspension containing the equivalent of 100-1000 mg cefuroxime.

Doses employed for human treatment will typically be in the range 100-3000 mg cefuroxime per day, e.g. 250 to 2000 mg cefuroxime per day for adults and 125 to 1000 mg cefuroxime per day for children, although
5 the precise dose will depend on inter alia the frequency of administration.

The following Examples illustrate the invention.

The cefuroxime axetil used in the Examples was highly pure spray dried amorphous material prepared as described in British Patent Specification No. 2127401 with a mean particle diameter by volume in the range 5-50 microns (μm).

Revel A is a commercial food grade of stearic acid, Hyfac is a commercial grade of stearic acid, Dynasan 112 is glyceryl trilaurate and Dynasan 114 is glyceryl trimyristate. Revel A, Hyfac, Dynasan 112 and Dynasan 114 are all tradenames.

Stearic acid BPC is specified as a mixture of fatty acids, chiefly stearic and palmitic acids in the British Pharmaceutical Codex (1973). In the United States 'National Formulary XV, 1980', stearic acid USNF is specified as containing not less than 40% stearic acid, not less than 40% palmitic acid and not less than 90% of stearic and palmitic acids.

Particle size measurements for Examples 1 to 3 were made by optical microscopy, Coulter Counter and laser light scattering using the following methods:

1. Optical Microscopy.

A small sample of lipid coated material was suspended on a microscope slide in silicone fluid and the particles were viewed and counted at x 100 magnification using an Imanco FMS microscope.

For each batch two slides were prepared and nine fields counted per slide. The particles were sized relative to a British Standard graticule (BS 3406, 1961) and assigned to size bands ranging from $>60\mu\text{m}$ to $<7.5\mu\text{m}$. The number count in each size band was recorded and used to calculate a volume mean diameter (VMD) using the following formula:-

$$\frac{\sum_{i=1}^m N(\chi_i) \chi_i^4}{\sum_{i=1}^m N(\chi_i) \chi_i^3}$$

$N(\chi_i)$ = number in given size band

χ_i = mid point of size band

2. Coulter Counter.

A small sample of lipid coated material was suspended in Coulter dispersant on a microscope slide. A quantity of this dispersed sample was added to the measuring beaker of the Coulter Counter, containing a 1% solution of sodium chloride in distilled water filtered through a 0.45 μ m Millipore filter, until the concentration index on the Coulter Counter (model TALL) registered between 5 and 10%. The beaker contents were then sonicated for 30 seconds, replaced in the Coulter Counter and stirred for one minute before a reading was taken. A number count was taken of particles in a number of size bands in the range 8.0 μ m to 128.0 μ m. The count was repeated after a total of four minutes stirring.

A mean of the one and four minute counts was taken for each size band and used to calculate a VMD (formula as described in Method 1).

The measurement was repeated from the start of sample preparation for a minimum of five separate samples per batch. The five VMD values were averaged to give a single composite mean.

Except where otherwise stated all the references herein to mean diameters by volume were measured by the Coulter Counter method.

3. Laser Light Scattering

A 5 mg sample of lipid coated material was added to 5 ml of 0.25% Tween 80 in distilled water and sonicated for 60 seconds. The sample vial was inverted twice, to mix the contents, and the sample was then added dropwise to the measuring cell of a Malvern 3600 E-type Particle Sizer until a beam obscuration of 0.2 was obtained. Readings were taken after one and four minutes stirring in the sample cell.

The VMD value for each sample was calculated. Measurements on a minimum of five samples were carried out on each batch and a composite mean produced.

Example 1

A dispersion of amorphous cefuroxime axetil (150g) in Stearic Acid powder BPC (850g) was prepared by melting the lipid, raising the temperature of the molten lipid to a temperature of about 15°C above its melting point and adding the cefuroxime axetil with mixing.

The molten lipid/cefuroxime axetil dispersion was fed into a spray drier/chiller apparatus using a peristaltic pump and atomised using an external mixing two fluid nozzle [nozzle outlet dimensions 2.54 mm (liquid orifice) and 3.81 to 4.57 mm (annular atomising fluid orifice)] with air at a temperature of 65-70°C and an atomising pressure of about 345 kPa (50 psi). The product was chilled using a stream of air fed into the spray chamber at ambient temperature and the solidified product was collected in a cyclone separator.

Examples 2

A dispersion of amorphous cefuroxime axetil (150g) in Stearic Acid powder BPC (850g) was prepared from a dry mix of the ingredients by melting the lipid, and holding the temperature at about 15°C above the melting point of the lipid.

The molten lipid/cefuroxime axetil dispersion was pumped into a spray drier/chiller apparatus at a rate of 300-500ml/minute and atomised using an internal mixing two fluid nozzle (supplied by Delavan Limited, Widnes, Cheshire catalogue number 32163-1 and as described in British Patent Specification No. 1412133) with air at a temperature of 65-70°C and an atomising pressure in the range of 276-345 kPa (40-50 psi). The product was chilled using a stream of air fed into the spray chamber at ambient temperature and the solidified product was collected by gravity.

Example 3

A dispersion of amorphous cefuroxime axetil in Stearic Acid powder BPC was prepared as in Example 2.

The molten lipid/cefuroxime axetil dispersion was pumped using a gear pump into a spray drier/chiller apparatus and atomised using an external mixing two fluid nozzle (2.0 mm bore) with air at a temperature of 75°C and an atomising pressure of 310 kPa (45 psi). The product was chilled using a stream of air fed into the spray

chamber at ambient temperature and the solidified product was collected in a cyclone separator.

The following particle sizes were recorded for batches of material prepared according to the processes described in Examples 1-3 :-

5

10

15

20

EXAMPLE NO	MALVERN 3600 E-TYPE PARTICLE SIZER	COULTER COUNTER TAII	OPTICAL MICROSCOPY IMANCO FMS
1	44.91 μm n = 10	48.73 μm n = 5	42.07 μm n = 2
2 BATCH A	43.93 μm n = 20	38.80 μm n = 5	40.10 μm n = 2
2 BATCH B	55.56 μm n = 10	44.43 μm n = 5	43.86 μm n = 2
3	29.46 μm n = 10	37.21 μm n = 10	35.18 μm n = 2

25

All particle sizes are expressed as VMD.

n = number of samples measured.

Example 4

30

35

A dry mix of cefuroxime axetil (124g) and Stearic Acid powder BPC (676g) was heated to 68°C with stirring to melt the lipid and form a suspension. The molten lipid/cefuroxime axetil dispersion was transferred to a spray cooling chamber at a rate of about 400ml/minute by applying pressure to the melt vessel. This was then atomised using an internal mixing two fluid nozzle (as described in Example 2), with air at a temperature of 78°C and a pressure of 380 kPa (55 psi). The product was cooled in a stream of air fed into the spray chamber and

the solidified material collected by gravity.

Median particle diameter by volume (Coulter counter) 51 μm

Cefuroxime axetil content 15.4%

5 Example 5

A dispersion for lipid-coating was prepared by melting the lipid, raising the temperature of the molten lipid to a temperature of 15°C above its melting point and adding the appropriate amount of cefuroxime axetil with mixing using a high shear mixer.

10 The molten lipid/cefuroxime axetil dispersion was pumped into a conventional spray drier/chiller apparatus with a spray chamber height of 1.82m at a rate of approximately 300ml/minute and atomised using an external mixing two fluid nozzle (as described in Example 1) at an atomising pressure in the range of 275 to 414 kPa (40 to 60
15 psi). The product was chilled using a stream of air fed into the spray chamber at 7-11°C. The solid product was collected in a cyclone separator.

The following mixtures of cefuroxime axetil and various lipids were spray chilled to give taste-masked lipid-coated particles of
20 cefuroxime axetil. The diameters of the particles obtained were determined by optical microscopy using a "Quantimet 970" Image Analyser.

	<u>% w/w</u>	<u>Weight (g)</u>
25 a) Stearic acid powder BPC	85	850
Cefuroxime axetil	15	150
Mean particle diameter by number 7.18 μm (95% of the total particles obtained had a diameter of less than 22 μm .)		
30 Mean particle diameter by volume 41.9 μm .		
b) Hyfac	85	850
Cefuroxime axetil	15	150
Mean particle diameter by number 7.93 μm (95% of the total particles obtained had a diameter of less than 25 μm .)		
35 Mean particle diameter by volume 47.5 μm .		

c) Stearic acid powder BPC	42.5	212.5
Dynasan 112	42.5	212.5
Cefuroxime Axetil	15	75.0

Mean particle diameter by number $8.38\mu\text{m}$ (95% of the total particles obtained had a diameter of less than $32\mu\text{m}$.)

Mean particle diameter by volume $51.0\mu\text{m}$.

d) Dynasan 114	85	425
Cefuroxime axetil	15	75

Mean particle diameter by number $7.32\mu\text{m}$ (95% of the total particles obtained had a diameter of less than $21\mu\text{m}$.)

Mean particle diameter by volume $47.1\mu\text{m}$.

Example 6

Maltodextrin coated cefuroxime axetil particles were prepared by dispersing maltodextrin (400g), tutti-frutti flavour (1g) and starch 1500 (25g) in distilled water (to 1L) by high shear mixing. Cefuroxime axetil (100g) was dispersed in this suspension using high shear mixing and the suspension was then spray dried using conventional spray drying techniques. The product was collected in a cyclone separator.

The maltodextrin coated cefuroxime axetil was then coated with Stearic acid BPC as described in Example 5.

	<u>% w/w</u>	<u>Weight (g)</u>
Stearic acid powder BPC	60	600
Maltodextrin coated cefuroxime axetil	40	400

Mean particle diameter by number $7.51\mu\text{m}$ (95% of the total particles obtained had a diameter of less than $23\mu\text{m}$).

Mean particle diameter by volume $46.0\mu\text{m}$.

Example 7

Using the processes described in Examples 5 and 6 the following mixtures of cefuroxime axetil and various lipids were spray chilled to give taste-masked lipid-coated particles of cefuroxime axetil.

		<u>% w/w</u>	<u>Weight (g)</u>
	a) Stearic acid powder BPC	55	611
	Maltodextrin coated cefuroxime axetil	45	500
5	b) Stearic acid powder BPC	80	800
	Cefuroxime axetil	20	200
	c) Revel A	80	800
10	Cefuroxime axetil	20	200
	d) Cetostearyl alcohol	85	850
	Cefuroxime axetil	15	150
15	e) Cetostearyl alcohol	60	600
	Maltodextrin coated cefuroxime axetil	40	400
	f) Hyfac	60	600
	Maltodextrin coated cefuroxime axetil	40	400
20	g) Stearic acid powder USNF	90	900
	Cefuroxime axetil	10	100
	h) Stearic acid powder USNF	40	200
25	Dynasan 112	40	200
	Cefuroxime axetil	20	100
	i) Stearic acid powder BPC	42.5	212.5
	Dynasan 114	42.5	212.5
30	Cefuroxime axetil	14	75
	j) Stearic acid	42.5	212.5
	Palmitic acid	42.5	212.5
	Cefuroxime axetil	15	75
35	k) Stearic acid	40	200
	Palmitic acid	40	200
	Cefuroxime axetil	20	100

Pharmaceutical Example

Stearic Acid BPC coated cefuroxime axetil is combined with sucrose and a proprietary flavouring in the proportions shown below. These materials are blended, then granulated by conventional means using water as the granulation fluid. After drying, the granules may be screened to remove any agglomerates, and they are then filled into bottles. A suspension for oral administration is produced by constitution with water to provide 125 mg of cefuroxime per 5 ml of suspension.

<u>Ingredient</u>	<u>% w/w</u>
Stearic Acid BPC coated cefuroxime axetil	24.92
Sucrose	74.75
Flavour (fruits of the forest)	0.33

CLAIMS:

1. A composition comprising cefuroxime axetil in particulate form, the particles being provided with integral coatings of a lipid or a mixture of lipids which are insoluble in water and which serve
5 to mask the bitter taste of cefuroxime axetil upon oral administration but which disperse or dissolve on contact with gastro-intestinal fluid.
2. A composition as claimed in claim 1 wherein
10 the lipid or mixture of lipids has a melting point in the range of from 30 to 80°C.
3. A composition as claimed in claim 2 wherein the lipid or mixture of lipids has a melting point
15 in the range of from 40 to 70°C.
4. A composition as claimed in claim 1 wherein the lipid or mixture of lipids comprises one or more straight chain aliphatic carboxylic acids having
20 from 10 to 30 carbon atoms.
5. A composition as claimed in claim 4 wherein the mixture of lipids comprises a mixture of stearic and palmitic acids in a ratio of from 3:7 to 7:3
25 by weight.
6. A composition as claimed in claim 5 wherein the mixture of stearic and palmitic acids is in a ratio of about 1:1 by weight.
30
7. A composition as claimed in any preceding claim containing from 5 to 90% by weight of cefuroxime axetil.

8. A composition as claimed in claim 7 containing from 10 to 30% by weight of cefuroxime axetil.

9. A composition as claimed in any preceding claim
5 containing amorphous cefuroxime axetil.

10. A composition as claimed in claim 9 wherein the cefuroxime axetil is spray-dried cefuroxime axetil in the form of hollow microspheres.

10

11. A composition as claimed in any preceding claim wherein the coated particles have diameters in the range from 1 to 250 microns

15 12. A composition as claimed in any preceding claim wherein the coated particles have a mean diameter by volume of less than 100 microns.

13. A process for the preparation of a composition
20 as claimed in claim 1 which comprises dispersing particulate cefuroxime axetil in a molten lipid or mixture of lipids, atomising the dispersion to provide particles having integral coatings of the lipid or mixture of lipids and cooling and collecting the
25 coated particles thereby obtained.

14. A process as claimed in claim 13 wherein the lipid or mixture of lipids is as defined in any of claims 2 to 6.

30

15. A process as claimed in claim 13 or claim 14 wherein the dispersion is atomised by a pneumatic nozzle atomiser.

35 16. A process as claimed in claim 15 wherein the atomiser is an internal mixing two-fluid nozzle atomiser.

17. A process as claimed in claim 15 or claim 16 wherein the molten dispersion is atomised at a temperature which is in the range of 10 to 20°C above the melting point of the lipid or mixture of lipids used.

5

18. A process as claimed in any of claims 15 to 17 wherein the particulate cefuroxime axetil prior to coating has a mean particle diameter by volume in the range of from 5 to 50 microns.

10

19. A process as claimed in any of claims 15 to 18 wherein the amounts of particulate cefuroxime axetil and lipid or lipid mixture used are such as to provide coated particles containing from 5 to 15 50% by weight of cefuroxime axetil.

20. A process as claimed in claim 19 wherein the amounts of particulate cefuroxime axetil and lipid or lipid mixture used are such as to provide coated 20 particles containing from 5 to 30% by weight of cefuroxime axetil.

21. A process as claimed in any of claims 15 to 20 wherein the dispersion is atomised to provide 25 coated particles having diameters in the range from 1 to 250 microns.

22. A process as claimed in any of claims 15 to 21 wherein the dispersion is atomised to provide 30 coated particles having a mean diameter by volume of less than 100 microns.

23. A process as claimed in claim 22 wherein the dispersion is atomised to provide coated particles 35 having a mean diameter by volume of from 20 to 100 microns.

24. A process as claimed in claim 23 wherein the dispersion is atomised to provide coated particles having a mean diameter by volume of from 30 to 60 microns.

5

25. A pharmaceutical composition for oral administration comprising a composition as claimed in claim 1, or as prepared by a process as claimed in claim 13, together with one or more pharmaceutical carriers or excipients.

10

26. A pharmaceutical composition as claimed in claim 25 in the form of granules.

15

27. A pharmaceutical composition as claimed in claim 25 in the form of an aqueous suspension.

20

28. A pharmaceutical composition as claimed in claim 27 containing an orally acceptable solute serving to assist in maintaining the taste-masking properties of the lipid coating.

25

29. A pharmaceutical composition as claimed in claim 28 wherein the solute is sugar in the concentration range 50 to 85 weight percent.

30. A pharmaceutical product as claimed in claim 1, substantially as herein described.

30

31. A process as claimed in claim 13 substantially as herein described.

32. A pharmaceutical composition as claimed in claim 25 substantially as herein described.

35